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In recent years, there has been a revival of interest in metabolic changes of cancer cells 
as it has been noticed that malignant transformation and metabolic reprogramming are 
closely intertwined. The pentose phosphate pathway (PPP) is one of the fundamental 
components of cellular metabolism crucial for cancer cells. This review will discuss 
recent findings regarding the involvement of PPP enzymes in several types of cancer, 
with a focus on hepatocellular carcinoma (HCC). We will pay considerable attention to 
the involvement of glucose-6-phosphate dehydrogenase, the rate-limiting enzyme of 
the PPP. Subsequently, we discuss the inhibition of the PPP as a potential therapeutic 
strategy against cancer, in particular, HCC.
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iNTRODUCTiON
Over the past 20 years, there has been a growing interest in tumor metabolism and, in particular, 
glucose metabolism. Thus, reprogramming of energy metabolism by tumor cells has now been 
acknowledged as one of the crucial hallmarks of cancer (1, 2). One of the most striking metabolic 
alterations in cancer cells—a significant increase in glycolytic activity even in the presence of abun-
dant oxygen—was described by Otto Warburg over 80 years ago (3, 4) and it was thought to be 
“the origin of cancer cells” (5). However, the real relevance of these metabolic features in cancer 
development has been subject of controversy over time and extensively debated after Warburg’s 
initial discovery (6). Recent years have witnessed a resurgence of interest in cancer metabolism, as 
it became evident that multiple signaling pathways, affected by genetic mutations and/or the tumor 
microenvironment, have a deep impact on tumor cell metabolism. These metabolic alterations con-
stitute a selective advantage for tumor growth, proliferation, and survival as they provide support to 
the crucial needs of tumor cells, such as increased energy production, macromolecular biosynthesis, 
and maintenance of redox balance (7–9).
In this regard, it should be underlined that altered glucose metabolism involves not only glycolysis 
but also other metabolic pathways requiring glucose utilization, such as the pentose phosphate 
pathway (PPP), one of the pivotal components of cell metabolism. The PPP has gained recognition 
as it helps tumor cells to satisfy their anabolic demands and maintains the redox homeostasis of 
cells. This review will summarize the observations regarding the involvement of the PPP in cancer, 
in particular the role of glucose-6-phosphate dehydrogenase (G6PD) and its relevance for possible 
therapeutic approaches.
THe ROLe OF THe PPP
The PPP, also known as phosphogluconate pathway or the hexose monophosphate shunt, branches 
from glycolysis as the first committed step of glucose metabolism, which is catalyzed by hexokinases 
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phosphorylating glucose, in order to generate glucose-6-phos-
phate (G6P). This reaction is considered to be the most relevant 
step in glucose metabolism as G6P is at the convergence point 
of glycolysis, PPP, hexosamine synthesis pathway, and glycogen 
synthesis (2, 10). The PPP is composed of two functionally 
interrelated branches: the oxidative and the non-oxidative. In 
the oxidative arm of the PPP, which is a major source of reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) and 
ribulose-5-phosphate (Ru5P), the first of three irreversible reac-
tions initiates when G6P is dehydrogenated by G6PD, to yield 
NADPH and 6-phosphogluconolactone. This product is next 
hydrolyzed by phosphogluconolactonase to generate 6-phos-
phogluconate. The last reaction is the oxidative decarboxylation 
of 6-phosphogluconate, catalyzed by 6-phosphogluconate 
dehydrogenase (6PGD), which yields a second NADPH and 
Ru5P. The next generation of ribose-5-phosphate from Ru5P 
and its conversion to phosphoribosyl pyrophosphate provides 
the backbone for the synthesis of ribonucleotides (10–13). The 
non-oxidative arm of the PPP generates pentose phosphates for 
ribonucleotide synthesis in a series of reversible reactions that 
produce also other metabolites, such as fructose-6-phosphate 
(F6P) and glyceraldehyde-3-phosphate (G3P) (14). Depending 
on cellular metabolic needs, while F6P can be converted back to 
G6P to replenish oxidative PPP to generate additional NADPH, 
G3P can be used in the glycolysis. The two main enzymes involved 
in the non-oxidative branch of the PPP are transketolase (TKT) 
and transaldolase (TALDO) (10, 13). Among the most important 
cell conditions that significantly affect PPP activity are the need of 
a high proliferation rate and NADPH requirement (15).
PPP eNZYMeS AND THeiR iNvOLveMeNT 
iN CANCeR
The generation of pentose phosphates to ensure elevated nucleic 
acid synthesis and NADPH production make the PPP pathway 
particularly critical for tumor cells. NADPH is required not 
only for fatty acid and cholesterol biosynthesis but also for the 
generation of reduced glutathione (GSH), a major scavenger 
of reactive oxygen species (ROS) (16). PPP activation has been 
widely demonstrated in different types of cancer and associated 
with invasion, metastasis, angiogenesis, and response to chemo-
therapy and radiotherapy (15, 17). Moreover, accumulating data 
have reported upregulation of several enzymes of both oxidative 
and non-oxidative branches of the PPP in tumor cells. This sec-
tion will provide a summary of these observations.
GLUCOSe-6-PHOSPHATe 
DeHYDROGeNASe
Initial studies on G6PD, the rate-limiting enzyme of the oxidative 
arm of the PPP, mostly focused on erythrocytes, as individuals 
susceptible to hemolytic anemia show genetically inherited G6PD-
reduced activity (18, 19). Following these observations, it was 
found that G6PD is highly conserved in most mammalian species 
(20) and is present in many normal tissues, such as mammary and 
adrenal glands, adipose tissue, spleen, lung, liver, and neuronal 
cells (21–26). In the liver and adipose tissue, the regulation of 
the G6PD activity depends on mechanisms involving changes in 
the NADPH requirements; indeed, an increase in the NADPH 
consumption is paralleled by an increase in the G6PD levels (27). 
Moreover, hepatic G6PD is also regulated by nutritional signals, 
including a high-carbohydrate diet, polyunsaturated fatty acids, 
and hormones, such as insulin and glucocorticoids (20, 28).
Numerous studies have revealed a significant upregulation 
of G6PD in tumor cells and neoplastic tissues (Table 1). First of 
all, Board et al. reported a high enzymatic activity of G6PD in 
H.Ep.2 cells, a cell line considered to originate from a carcinoma 
of the larynx (29). Later on, analysis of intracellular G6PD activity 
in various cancer cell lines, such as human cervical carcinomas, 
esophageal carcinomas, hepatomas, lung adenocarcinomas, and 
colon adenocarcinomas, revealed that G6PD was particularly 
overexpressed in human esophageal cancer cell lines (30). In the 
same study, it was shown that following transfection of NIH 3T3 
fibroblasts with human G6PD cDNA, G6PD-overexpressing cells 
were not contact inhibited, displayed anchorage-independent 
growth in soft agar, and divided more quickly. In nude mice, 
G6PD-overexpressing cells gave rise to rapidly growing, large 
fibrosarcomas, characterized by the abundance of new blood 
vessels, therefore suggesting angiogenic properties of high levels 
of G6PD (30). In animal models of carcinogenesis, increased 
G6PD activity was observed in estrogen-induced kidney tumors 
in Syrian hamsters when compared to untreated controls (31). 
Using a histochemical technique, an increased G6PD activity 
was reported in human cervical cancer and colon carcinoma 
(32, 33). Elevated G6PD activity in cervical intraepithelial 
neoplasia, as well as in endometrial carcinoma, was further 
confirmed in different studies (34–36); G6PD activity was also 
significantly higher in human colon cancer specimens when 
compared with normal epithelium and in chemically induced 
mice colon carcinomas (37). Moreover, enhancement of G6PD 
activity during cell cycle progression, in particular S/G2 phases, 
was also reported in the human colon cancer cell line HT29 (38). 
Upregulation of G6PD levels was described in papillary thyroid 
carcinoma (PTC) (39) and renal cell cancer (40). On the other 
hand, a very weak G6PD activity was observed in lung cancer 
(33), and variable results were obtained in breast carcinoma cells 
(41, 42). However, a recent study by Rao et al. has suggested that 
O-GlcNAcylation of G6PD, leading to G6PD activation and to an 
increase of glucose flux through the PPP, is increased in human 
non-small cell lung cancer (43). Furthermore, G6PD glycosyla-
tion was shown to promote cancer cell proliferation in vitro and 
tumor growth in vivo (43). Not only increased G6PD activity was 
found in prostatic carcinoma when compared to benign hyper-
plasia but a positive correlation between its enzymatic activity 
and differentiation degree as well as clinical stage was observed 
(44). mRNA, protein levels, and G6PD activity were significantly 
higher in human melanoma cell line (A375) compared to those of 
normal human epidermal melanocytes. In this study, delayed for-
mation and reduced growth of tumor cells in nude mice injected 
with A375-G6PD-deficient cells were also demonstrated (45). 
In gastric cancer, Kekec et al. demonstrated that G6PD activity 
was higher in tumoral tissue than in normal one (46). Moreover, 
Wang et al. observed that G6PD overexpression in this tumor type 
TAbLe 1 | Glucose-6-phosphate dehydrogenase (G6PD) overexpression in different tumor types.
Tumor type Species analyzed Method(s) Reference
Breast tumor H Enzymatic activity Cohen (41)
H Enzymatic activity Bokun et al. (42)
Cervical tumor H Enzymatic activity Cohen and Way (32)
H Enzymatic activity Dut¸u et al. (34)
H Enzymatic activity Jonas et al. (36)
Colon tumor H Enzymatic activity Cohen et al. (33)
H, M Enzymatic activity Van Driel et al. (37)
H cell line Enzymatic activity Vizán et al. (38)
H Enzymatic activity Kekec et al. (46)
Endometrial tumor H Enzymatic activity Hughes (35)
Esophageal tumor H cell line Enzymatic activity, RNA (NB) and protein (WB) levels Kuo et al. (30)
Gastric tumor H Enzymatic activity Kekec et al. (46)
H mRNA (qRT-PCR), protein (IHC) levels Wang et al. (47)
Kidney tumor SH Enzymatic activity Roy and Liehr (31)
H Enzymatic activity Langbein et al. (40)
Laryngeal tumor H cell line Enzymatic activity Board et al. (29)
Liver tumor R Enzymatic activity Weber and Cantero (68)
R Enzymatic activity Weber and Morris (69)
R Enzymatic activity Hacker et al. (70)
R Enzymatic activity Ledda-Columbano et al. (75)
R Enzymatic activity Baba et al. (71)
R Enzymatic activity and mRNA levels (NB) Stumpf and Bannasch (72)
R Enzymatic activity Frederiks et al. (74)
M Serum G6PD El-Ashmawy et al. (78)
H, H cell line mRNA levels (qRT-PCR), protein (WB, IHC) levels Hu et al. (79)
H, H cell line Enzymatic activity, mRNA (qRT-PCR), protein (WB) levels Hong et al. (80)
H, H cell line Enzymatic activity, mRNA (qRT-PCR), protein (IF, WB) levels Liu et al. (88)
R, R cell line, H Enzymatic activity, mRNA (qRT-PCR), protein (WB, IHC) levels Kowalik et al. (76)
H Transcriptome sequencing Xu et al. (53)
Lung tumor H, H cell line, M G6PD glycosylation Rao et al. (43)
Melanoma H cell line, M Enzymatic activity, mRNA (qRT-PCR), protein levels (WB) Hu et al. (45)
Prostate tumor H Enzymatic activity Zampella et al. (44)
Thyroid tumor H mRNA levels (qRT-PCR) Chen et al. (39)
H, human; M, mouse; R, rat; SH, Syrian hamster; IF, immunofluorescence; IHC, immunohistochemistry; qRT-PCR, quantitative real-time PCR; WB, western blot, NB, northern blot.
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positively correlated with different clinicopathological features 
analyzed, such as tumor size, invasion, metastasis, and survival 
(47). Overall, these results suggest that G6PD overexpression may 
represent an independent predictor of poor prognosis for patients 
with gastric cancer.
TKT AND TALDO
Although the non-oxidative arm of the PPP has been underrated 
for a long time, an increasing amount of experimental evidence 
suggests its importance in cancer cell metabolism. The need of 
rapidly proliferating cancer cells to generate ribonucleotides 
causes an elevated expression of the enzymes involved in the 
non-oxidative branch of the PPP, as TALDO and TKT can divert 
F6P and G3P from glycolysis to the PPP, in order to increase 
ribonucleotides production (14). Previous studies in pancreatic 
adenocarcinoma cells showed that pentose cycle reactions con-
tribute to approximately 85% of de novo ribose synthesis in RNA, 
the majority of which were derived from the non-oxidative path-
way (48). In normal tissues, while the highest TALDO activities 
have been reported in thymus and intestinal mucosa, the highest 
TKT activity has been observed in kidney, intestinal mucosa, 
thymus, and liver (49). TALDO1 has been found increased in 
the head and neck squamous cell carcinoma (SCCHN), as well 
as in brain, bladder, breast, and esophageal cancers (50–52). In 
addition to higher TALDO1 expression levels, genetic variations 
in the TALDO1 gene has been also evaluated; the presence of 
specific polymorphisms in the TALDO1 gene has been associ-
ated with an increased occurrence of SCCHN (51). Finally, the 
relevance of human TALDO has been recognized not only for its 
involvement in cancer but also in different autoimmune diseases, 
such as multiple sclerosis and rheumatoid arthritis (52).
As to HCC, although the increased TALDO activity was 
demonstrated in liver tumors (49, 53), the role of TALDO in 
liver cancer does not seem univocal. Hanczko et al. showed that 
Taldo1-deficient mice spontaneously developed HCC preceded 
by the occurrence of steatosis, steatohepatitis, and cirrhosis and 
displayed enhanced susceptibility to acetaminophen-induced 
liver failure (54). Thus, further studies are needed to clarify the 
role of the non-oxidative branch of PPP in HCC development.
With regard to TKT, three human TKT genes have been 
described so far: TKT, transketolase-like-1 (TKTL1), and 
transketolase-like-2 (TKTL2). While most non-transformed 
cells possess TKT activity and very low TKTL enzymes activity, 
TKTLs are often present in malignant tissues (15, 55). Coy et al. 
first described TKTL1 and suggested that it may have an altered or 
reduced TKT activity (56); however, this aspect remains contro-
versial (57). Nonetheless, the contribution of TKTL1 in tumor cell 
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metabolism has been demonstrated by the finding that inhibition 
of TKTL1 in different tumor cells caused a significantly decrease 
in cell proliferation (58, 59). While overexpression of mutated 
TKTL1 has been reported in urothelial and colorectal cancer 
and correlated with tumor invasiveness as well as predicted poor 
patient outcome, TKT and TKTL2 expression were not altered 
in this study (60). Immunohistochemistry analysis revealed 
TKTL1 overexpression in 86% of breast cancer specimens, 
which correlated significantly with Her2/neu overexpression 
(61). Furthermore, increased expression of TKTL1 was detected 
in most PTC cases, compared with their corresponding normal 
tissues, whereas TKT and TKTL2 did not result upregulated. A 
significant association was also found between TKTL1 protein 
expression and the presence of multifocality, extra-thyroidal 
extension, vascular invasion, and lymph-node metastases (62). 
Noteworthy, similar results were also observed in gastric (63) and 
renal cancer (40), nasopharyngeal carcinoma (64), glioblastoma 
multiforme (65), and head and neck squamous cell carcinoma 
patients (66), implicating TKTL1 as a novel candidate oncogene 
(15, 66).
On the other hand, a recent transcriptome sequencing 
revealed that TKT was the most abundantly expressed and most 
profoundly upregulated PPP enzyme in HCC (53). TKT expres-
sion was positively associated with aggressive clinicopathological 
HCC features (presence of venous invasion, increased tumor size, 
absence of tumor encapsulation). The fact that TKTL1 and TKTL2 
resulted almost undetectable, suggests that TKT may be the pre-
dominant form in the liver tissue. Accordingly, the use of TKT 
inhibitor oxythiamine (OT) significantly sensitized human HCC 
cells to sorafenib treatment in vitro and suppressed tumor growth 
in vivo (53). These results, together with those stemming from the 
analysis of TALDO, suggest that the role of non-oxidative branch 
of PPP in HCC may not be the same as that of other tumors, and 
its full understanding requires further investigation.
G6PD AND HCC
Of all the PPP enzymes discussed above, G6PD has been the most 
studied with respect to HCC, the second most common cause 
of cancer mortality worldwide. This tumor is characterized by 
a poor patient outcome due to limited therapeutic options (67), 
and it has been acknowledged as a typical example of glucose 
metabolism reprogramming in cancer cells (2). In rat experi-
mental models consisting of normal and regenerating livers and 
cell lines, G6PD activity was found to be highly increased in the 
Novikoff hepatoma (68) and in eight rapidly growing hepatomas, 
but not in the one displaying a slow growth rate (69). An increase 
in G6PD-positivity in preneoplastic hepatic lesions and HCC, 
associated with a high labeling index, has been also reported in 
different studies using a rat protocol of hepatocarcinogenesis 
induced by N-nitrosomorpholine (70–72). Later on, Frederiks 
et  al. showed that diethylnitrosamine (DENA)-induced rat 
preneoplastic lesions were characterized by a 25-fold increase 
of G6PD activity when compared with the surrounding tissue 
(73, 74). Elevated G6PD activity, mRNA, and protein levels 
were also observed in rat preneoplastic nodules and HCC 
(75, 76) induced by the resistant-hepatocyte (R-H) protocol of 
carcinogenesis (77). Interestingly, a significant increase in serum 
G6PD activity has been recently seen in mice with HCC induced 
by DENA/thioacetamide (78).
Using isobaric tag for relative and absolute quantitation 
(iTRAQ) and LC-MS/MS, in order to determine novel proteins 
associated with HCC, Hu et  al. found an increased expression 
of G6PD in HBV-associated HCC patients and in the HBV 
DNA-stably transfected cell line HepG2.2.15 (79). Moreover, the 
same study reported that G6PD silencing significantly inhibited 
HepG2 cell line invasion. In line with these observations, our 
recent data obtained from two different cohorts of patients 
who have undergone liver resection for HCC or liver biopsies 
demonstrated a significant G6PD upregulation in most of the 
tumors when compared to their peri-tumoral counterpart (76). 
Remarkably, such increase in G6PD expression was significantly 
associated with high-grade HCCs, and positively correlated 
with metastasis formation and decreased overall survival. The 
increased expression of G6PD appeared to be a general phenom-
enon, as stratification of patients according to their etiology did 
not reveal any significant association with the mRNA levels of 
the enzyme (76). The involvement of G6PD in HCC development 
stems also from the work by Hong et al., who observed that G6PD 
mRNA levels in HCC tissues, collected from patients undergoing 
HCC resection, were significantly increased when compared 
to normal liver and positively correlated with the pathological 
grade (80). The clinical importance of these data resulted also 
from the observation that lower expression of G6PD in patients 
who received sorafenib treatment after liver cancer surgery was 
significantly associated with better progression-free and overall 
survival. Furthermore, additional in  vitro studies showed that 
G6PD knockdown in HCC cell lines induced cellular senescence, 
as demonstrated by an increased number of cells positive for beta-
galactosidase (SA-β-GAL) staining and p21 expression. In vivo 
studies reinforced the relevance of G6PD in HCC progression, as 
G6PD suppression inhibited tumor growth in Huh7 orthotopic 
tumor and mouse xenograft models (81). A recent comparison 
of the expression of G6PD in pairs of human HCC and the corre-
sponding non-tumorous (NT) liver by transcriptome sequencing 
further confirmed a significant upregulation of G6PD in human 
HCCs (53).
6-PHOSPHOGLUCONATe 
DeHYDROGeNASe
Expression of 6PGD, the third enzyme in the oxidative PPP, 
has been frequently studied together with G6PD. In fact, both 
G6PD and 6PGD have been shown to be increased in cervical 
carcinoma (32, 34, 36), as well as in lung tumors (82). The critical 
role of 6PGD in cancer cell proliferation has been described in 
non-small cell lung carcinoma. 6PGD knockdown inhibited the 
growth of lung cancer cells by inducing senescence, as demon-
strated by the increased number of beta-galactosidase (SA-β-
GAL)-positive cells and p53 accumulation and retarded tumor 
growth in a mouse xenograft model (81). An increased activity 
of 6PGD was also reported in rat hepatic preneoplastic lesions 
induced by DENA or by the R-H model when compared with the 
surrounding parenchyma (73–75).
FiGURe 1 | Glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase, transketolase, and transaldolase modifications in 
normal regenerating liver following partial hepatectomy (A), preneoplastic lesions endowed with different aggressive behavior (b,C), and 
hepatocellular carcinoma (HCC) (D). Red color indicates positive staining for G6PD. Thickness of the arrows represents the magnitude of G6PD expression.
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PPP AND NRF2–KeLCH-LiKe  
eCH-ASSOCiATeD PROTeiN 1  
(KeAP1) PATHwAY
Pentose phosphate pathway activation has been suggested as a 
mechanism by which dysregulated NRF2–KEAP1 signaling pro-
motes cellular proliferation and tumorigenesis (83). Transcription 
factor NRF2 [NFE2L2, nuclear factor (erythroid-derived-2)- 
like 2] is known as a major sensor of oxidative stress in the cell. 
Under basal conditions, NRF2 is sequestered by cytoplasmic 
KEAP1 and targeted to proteasomal degradation. Exposure to 
electrophiles or ROS causes modification of the cysteine residues 
of Keap1, leading to its inactivation. Hence, NRF2 becomes 
stabilized and translocates to the nucleus, where it induces 
transcription of numerous antioxidant and detoxifying genes by 
binding to the antioxidant response elements in their regulatory 
regions (84, 85). The induction of these genes confers resistance 
against xenobiotic and oxidative stress. Several studies reported 
that either loss of NRF2–KEAP1 interaction or point mutations 
in the KEAP1 or NRF2 gene are often observed in human cancers, 
such as renal cell carcinoma, chronic lymphocytic leukemia, 
esophageal squamous cell carcinoma, HCC, non-small cell lung 
cancer, and others (86, 87). However, it should be underlined 
that the genes involved in the antioxidant response are not the 
only group of NRF2 target genes with possible relevance to 
cancer development. In fact, upregulation of both oxidative and 
non-oxidative PPP enzymes, including G6PD, 6PGD, TALDO, 
and TKT was demonstrated to drive metabolic reprogramming 
and NRF2-dependent proliferation in lung adenocarcinoma cells 
(A549) (83). With regard to the PPP–NRF2–KEAP1 regulation, in 
HBV-associated HCCs, it was also found that HBV can upregulate 
G6PD expression in hepatocytes through HBx-mediated Nrf2 
activation. HBx was shown to interact with p62 and Keap1 to 
generate HBx–p62–Keap1 aggregates in the cytoplasm, leading to 
the Nrf2 nuclear translocation and its activation (88). Moreover, 
we have recently shown (76) that G6PD upregulation occurred 
only in the highly proliferating aggressive cytokeratin-19 posi-
tive (KRT-19) rat preneoplastic hepatic nodules, characterized by 
activation of the NRF2–KEAP1 pathway, but not in slow-growing 
lesions (Figure 1). Accordingly, NRF2 silencing in rat HCC cells 
significantly decreased G6PD expression. In the same study, a 
positive correlation between NQO1, a NRF2 target gene, and 
G6PD expression in human HCC samples was also reported.
Recently, it has been proposed that NRF2 may coordinate the 
regulation of metabolic genes. In particular, gain of NRF2 func-
tion has been suggested to upregulate the expression of key genes 
involved in the PPP, such as G6PD, TKT, and 6PGD, by attenuat-
ing the expression of miRNA-1 (89). The control of gene expres-
sion by miRNAs—small, evolutionarily conserved, non-coding 
RNAs—has been frequently observed in a wide range of human 
pathologies, including cancer (90). Accordingly, KRT-19-positive 
preneoplastic nodules show an inverse correlation between 
TAbLe 2 | Glucose-6-phosphate dehydrogenase inhibitors.
inhibitor Tumor type analyzed Reference
Dehydroepiandrosterone Colon adenocarcinoma (106)
Preneoplastic liver lesions, HCC (103, 104)
Pancreatic carcinoma (48)
6-AN Colon cancer (116)
Mammary adenocarcinoma (111, 112, 115)
Lymphosarcoma (111, 112)
CB83 Mammary carcinoma (119)
Imatinib (Gleevec) Leukemia (122, 123)
Resveratrol Colon cancer (125)
Genistein Pancreatic adenocarcinoma (126)
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miRNA-1 and G6PD (76). Moreover, an increased expression 
of miRNA-1, paralleled by G6PD downregulation is observed in 
NRF2-silenced RH cells. Furthermore, a significant downregula-
tion of miRNA-1 levels was observed in 78% of human HCCs, 
when compared to matched non-cancerous liver cirrhotic (LC) 
tissues. Notably, a concomitant increase of G6PD expression in 
the same human HCCs compared to LC was reported (76). These 
studies suggest the existence of a NRF2–miR-1–PPP axis also in 
human HCC.
PPP AND HePATOCYTe PROLiFeRATiON
It has been proposed that the metabolism of highly dividing 
cells, either normal or neoplastic cells, is adapted to facilitate 
the uptake and incorporation of nutrients into the biomass 
(e.g., nucleotides, amino acids, and lipids) needed to produce a 
new cell (91). Since pentoses are required for DNA synthesis, it is 
not surprising that metabolic changes leading to increased G6PD 
expression occur in different cancers, including HCC. However, 
it is unclear whether the induction of the oxidative arm of PPP 
is required for the proliferation of normal cells. This is a crucial 
point to be addressed, since, ideally, therapeutic drugs directed 
against specific molecules should not harm normal cells. The 
liver is a perfect organ to address this question. Indeed, although 
adult liver is normally a quiescent organ, it is characterized by a 
rapid and highly synchronous proliferative activity in response 
to a reduction in liver mass caused by different stimuli (physical, 
chemical, nutritional, vascular, or virus-induced liver injury). In 
this context, liver regeneration after 70% partial hepatectomy 
(PH), introduced by Higgins and Anderson (92), represents a 
classic and well-recognized experimental model of rapid, con-
trolled, and reproducible cell proliferation in a mammalian organ 
system (93, 94). Following the removal of two-thirds of the liver, 
the residual lobes enlarge to restore the original liver mass and 
the whole process, in rats and mice, is completed within 5–7 days 
after surgery (95). Intriguingly, Heinrich et al. observed that there 
was no alteration in TALDO and TKT activity in regenerating 
liver 24  h after PH when compared with the sham-operated 
controls (49). Later on, other studies demonstrated that also the 
oxidative branch does not seem to be involved. Indeed, Weber 
and Cantero (68) observed that G6PD activity in rats undergoing 
PH and in sham-operated animals did not differ significantly. 
Moreover, it was reported that both G6PD and 6PGD activities 
were even lower 48 h after PH, in particular in intermediate and 
pericentral zones, when compared with the activity observed in 
control liver (96). In accordance with these results, a recently 
performed comparison of samples obtained 24 and 48  h after 
PH (time of maximal DNA synthesis and of the second peak 
of hepatocyte proliferation, respectively) with quiescent liver, 
demonstrated that G6PD mRNA and protein levels and its activ-
ity were found profoundly downregulated in regenerating liver 
following PH (76). Although the reason underlying this appar-
ently paradoxical effect is unknown, two possible explanations 
can be offered: (i) enhanced expression of G6PD is specific for 
cells destined to cancer progression, while liver regeneration can 
be sustained by pentoses generated by the non-oxidative PPP in a 
G6PD-independent manner, or by others sources. As recognized 
(2, 91), the balance between oxidative branch and non-oxidative 
branch of the PPP depends on the redox and metabolic status 
of the cell. Thus, it is likely that the primary role of oxidative 
PPP induction is to maintain the redox equilibrium in pre- or 
neoplastic hepatocytes characterized by high intracellular ROS 
levels, compared to the non-tumorigenic counterpart (10, 76). In 
this context, it is worth to mention that suppression of glycolysis 
by TIGAR which enabled a reduction of intracellular ROS, via 
increased PPP activity, has been reported in several cell lines 
(97) and in KRT-19-positive preneoplastic liver nodules (76); (ii) 
PPP is downregulated in regenerating liver to enable glycolysis, 
since energy production and biomass formation are the most 
important needs for the metabolic readjustment of the residual 
liver post-surgery (95). Overall, the results obtained in distinct 
experimental models (preneoplastic vs. normal liver) suggest that 
enhanced G6PD expression/activity is not required for normal 
hepatocyte proliferation, but represents a metabolic change 
restricted to the tumorigenic process instead. Intriguingly, G6PD 
expression appears to discriminate the most aggressive preneo-
plastic lesions from those that most likely undergo spontaneous 
regression (76) (Figure 1). In this context, it would be interesting 
to see whether G6PD expression might also be used to differenti-
ate human dysplastic nodules with different growth capacity.
TARGeTiNG G6PD iN CANCeR
Given the important role of the PPP in cancer metabolism, it 
is not surprising that targeting the PPP with selective and spe-
cific modulators has been widely considered as a relevant and 
challenging therapeutic option (98, 99). However, at present, 
only few PPP inhibitors are available, and their clinical use has 
been considered limited (see Table  2). Among them, there is 
an uncompetitive G6PD inhibitor, dehydroepiandrosterone 
(DHEA) which together with its sulfate form, represents the most 
abundant circulating steroid hormone in humans and is the major 
secreted product of the adrenal glands (100, 101). The molecular 
basis of this inhibition seems to be due to the binding of DHEA 
to the ternary enzyme–coenzyme–substrate ternary complex(es) 
(102). Administration of DHEA was able to inhibit the growth 
of early preneoplastic liver lesions and delay the progression 
to HCC of persistent liver nodules induced by the R-H model 
(103, 104). Growth inhibition was associated with a decrease in 
G6PD activity in preneoplastic hepatic nodules of DHEA-treated 
rats. In vitro studies by Tian et al. demonstrated that inhibition 
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of G6PD activity by DHEA abrogated cell growth and decrease 
cell anchorage of Swiss 3T3 fibroblasts (105). Anti-proliferative 
effect of DHEA coupled with G6PD inhibition was also observed 
in human colon adenocarcinoma HT29 cells (106), and DHEA 
treatment significantly reduced the efficiency of colony forma-
tion in soft agar of G6PD-overexpressing cells (30). Other studies 
considered administering DHEA or DHEA-sulfate in combina-
tion with OT, an irreversible inhibitor of TKT. Simultaneous 
treatment with DHEA and OT exerted an inhibitory effect on 
G6PD, which was associated with decreased cell proliferation 
in MIA PaCa-2 pancreatic carcinoma cells (48). However, more 
recently, it was proposed that the anti-tumorigenic effects of 
DHEA might not be due to G6PD inhibition, but rather to the 
malfunctioning of mitochondria and the consequent cessation 
of cell growth (107). This finding, together with the adverse side 
effects emerged in rodents after a long-term DHEA treatment 
(104), led to the use of DHEA analogs, which are more potent 
inhibitors of G6PD than the parent compound and do not cause 
major side effects (108, 109).
The oxidative PPP can be also blocked by 6-aminonicoti-
namide (6-AN), which induces the biosynthesis of 6-aminoni-
cotinamide adenine dinucleotide phosphate and subsequently 
inhibits the PPP at the level of 6PGD, leading to reduced NADPH 
production (110). 6-AN was initially reported to exert a promis-
ing antitumor activity in different experimental tumors, includ-
ing the Walker carcinoma 256, mammary adenocarcinoma 755, 
and lymphosarcoma 6C3HED (111, 112). Further studies have 
suggested that response to radiotherapy might depend on the 
activity of the PPP (113, 114). Indeed, the combined treatment 
of 6-AN and radiation achieved a higher percentage of tumor 
growth delay than either 6-AN or radiotherapy alone in mouse 
mammary carcinoma tumor model (115). In agreement with the 
observations that changes in PPP activity may also influence the 
response of tumor cells to chemotherapy, it has been reported 
that both DHEA and 6-AN not only were able to reverse the 
increase of G6PD and GSH but also inhibited multidrug resist-
ance in the doxorubicin-resistant human colon cancer cell line 
HT29-DX. These results suggest that G6PD inhibition may 
sensitize drug-resistant cancer cells to the cytotoxic effect of 
doxorubicin (116). Furthermore, colony-forming assays dem-
onstrated that pretreatment with 6-AN resulted in increased 
sensitivity to the cytotoxic effects of cisplatin in a variety human 
tumor cell lines (117). Unfortunately, the clinical use of 6-AN 
is hampered by its toxicity at high concentrations and its severe 
side effects, such as B-complex vitamin deficiency and a serious 
neurologic damage (112, 118).
A high-throughput screening approach performed to identify 
novel human G6PD inhibitors, selected few compounds that were 
even 100- to 1,000-fold more potent when compared with DHEA 
or 6-AN. Of the tested compounds, CB83 showed a significant 
inhibition on the viability of the mammary carcinoma cell line 
MCF10-AT1 (119). Some natural products, such as gallated 
catechins or rosmarinic acid, have been also proposed as G6PD 
inhibitors (120, 121). With regard to the non-specific inhibitors, 
it has been reported that treatment with Imatinib (Gleevec), a 
tyrosine kinase inhibitor designed to specifically target the BCR-
ABL oncogene protein, was able to decrease the activity of both 
hexokinase and G6PD in leukemia cells, leading to suppression 
of aerobic glycolysis (122, 123). Moreover, resveratrol (RSV, 
3,5,4′-trihydroxy-trans-stilbene), a phytoalexin found in the skin 
of red grapes and peanuts (124), suppressed cell cycle progression 
in HT29 advanced human colon cancer cells by downregulating 
two key enzymes of the PPP, G6PD, and TKT (125). In this group 
of compounds, also genistein, the isoflavonoid of the soy plant, 
was able to decrease G6PD and the activity of the pentose cycle 
in MIA pancreatic adenocarcinoma cells (126).
Unfortunately, the paucity of studies aimed at investigating the 
effect of G6PD inhibitors on HCC development is not sufficient to 
draw any possible conclusion on their efficacy. Nevertheless, the 
emerging evidence that increased hepatocyte G6PD expression 
is a feature unique to the tumorigenic process makes the search 
for reliable G6PD inhibitors a very attractive and stimulating 
topic. Indeed, the decreased NADPH generation following the 
treatment with inhibitors of the oxidative PPP (i) could represent 
a condition sufficient to selectively eradicate cancer cells by 
decreasing the resistance of pre- and neoplastic hepatocytes to 
intracellular ROS and (ii) might increase, in conjunction with 
already-approved therapy [i.e., inhibitors of thyrosine kinases 
(tki), such as sorafenib or other chemoterapeutic agents], the 
susceptibility of cancer cells to the treatment.
PeRSPeCTiveS
Oxidative PPP activation can help transformed cells to escape 
oxidative stress by increasing the intracellular redox power 
of cancer cells through enhanced NADPH production. It 
is thus obvious that we can look at the enzymes involved in 
this pathway as potential pharmacological targets. However, 
although significant evidence suggest that PPP enzymes might 
represent reliable prognostic markers in different tumor types, 
not sufficient efforts have been undertaken to establish the 
role of the enzymes involved in the PPP in cancer. Moreover, 
the therapeutic potential hidden in this metabolic pathway is 
strongly limited by the lack of specific pharmacological inhibi-
tors, as so far specific and effective inhibitors are unavailable. 
Indeed, the recent observation that anti-proliferative effects of 
DHEA are most likely not due to G6PD inhibition but rather to 
changes in mitochondrial gene expression highlights the need 
for novel selective G6PD inhibitors to investigate the impact 
of this enzyme on human diseases. Nevertheless, the emerg-
ing evidence that increased hepatocyte G6PD expression as a 
feature unique to the tumorigenic process makes the search for 
reliable G6PD inhibitors very attractive in the field of HCC. 
Indeed, the decreased NADPH generation following the treat-
ment with inhibitors of the oxidative PPP, (i) could represent 
a condition sufficient to selectively eradicate cancer cells by 
decreasing their resistance to high intracellular ROS levels; (ii) 
might increase, in conjunction with already-approved therapy 
[i.e., inhibitors of thyrosine kinases (tki), such as sorafenib or 
other chemoterapeutic agents], the susceptibility of cancer cells 
to anticancer drugs. The design of specific inhibitors targeting 
PPP is thus highly desirable as they might represent a useful 
therapeutic tool, in particular, for HCC. In conclusion, the 
growing interest in metabolic reprogramming of cancer cells 
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and the emerging evidence of the association between activa-
tion of oxidative PPP and tumor aggressiveness will hopefully 
fuel innovative approaches to unveil the role of this pathway in 
cancer therapy.
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